Explore

Trendline Trendline
DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding

EyePoint Inc. Reports Increased Losses Amid Phase 3 Clinical Trials Funding
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments

Sarepta Therapeutics Reports Q1 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
Viridian Therapeutics Raises $350 Million Through Convertible Notes and Stock Offerings

Viridian Therapeutics Raises $350 Million Through Convertible Notes and Stock Offerings

Viridian Therapeutics Raises $350 Million Through Convertible Notes and Stock Offerings
Trendline Trendline
Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market

Odyssey Therapeutics Sets Terms for $225 Million IPO Amid Resurgent Biotech Market
Trendline Trendline
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026

IDEAYA Biosciences Reports Positive Results and Business Updates for Q1 2026
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing

Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing

Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing
Trendline Trendline
NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week

NImmune Biopharma Presents Promising Data for IBD Treatment at Digestive Disease Week